临床医学工程

Clinical Medicine & Engineering

论著

  • Analysis of Performance Stability and Clinical Efficacy of OBERS - 3000 Hemodialysis Machine

    Lianghong Yin;Bo Hu;Lihua Luo;Lifeng Yang;Guanmin Wu;Liangyong Hu;Fanna Liu;Yu Chen;Peitian Yang;Long Xiao;Huiyuan Zheng;Tong Liu;Hongwei Hu;Chen Yun;Ying Huang;Xia Yu;Folan Li;Aiyun Cha;Xiangnan Dong;Huanhuan Liu;Mingming Ma;Yongpin Lu;Taksui Wong;Baozha

    Objective To explore the method of safety and efficacy validation of hemodialysis machine,and observe the clinical efficacy of OBERS-3000 multifunctional hemodialysis machine.Methods Randomized,open,two-phase crossover and positive control design,a total of 72 patients from two hospitals were included.OBERS-3000 multifunctional hemodialysis machine was the test machine,and the Fresenius 4008 series hemodialysis machine was as the control machine,indicators of blood routine test,serum electrolytes,liver and kidney function test,blood gas analysis,CRP were compared,body weight before and after hemodialysis,ultrafiltration volume were recorded,urea clearance index,urea reduction ratio were calculated.The XL90 conductivity meter was connected in series in the test machine,to monitor the temperature,conductance,venous pressure and arterial pressure during the dialysis in real time,and the measured value were compared with the machine monitoring value.Results Both of the test machine and the control machine could effectively eliminate creatinine,urea nitrogen and other uremic toxins,could continuously supply qualified dialysate,and precisely control the ultrafiltration volume.There were no significant differences in temperature,conductance,venous pressure and arterial pressure monitoring with the real time measured value by XL90 conductivity meter.Conclusions OBERS-3000 multifunctional hemodialysis machine can effectively eliminate uremic toxins,maintain electrolyte and acid-base balance,and can accurately display the monitoring parameters.

    2017年S1期 1-6页 [查看摘要][在线阅读][下载 366K]
    [下载次数:8 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Analysis of Performance Stability and Clinical Efficacy of OBERS - 3000 Hemodialysis Machine

    Lianghong Yin;Bo Hu;Lihua Luo;Lifeng Yang;Guanmin Wu;Liangyong Hu;Fanna Liu;Yu Chen;Peitian Yang;Long Xiao;Huiyuan Zheng;Tong Liu;Hongwei Hu;Chen Yun;Ying Huang;Xia Yu;Folan Li;Aiyun Cha;Xiangnan Dong;Huanhuan Liu;Mingming Ma;Yongpin Lu;Taksui Wong;Baozha

    Objective To explore the method of safety and efficacy validation of hemodialysis machine,and observe the clinical efficacy of OBERS-3000 multifunctional hemodialysis machine.Methods Randomized,open,two-phase crossover and positive control design,a total of 72 patients from two hospitals were included.OBERS-3000 multifunctional hemodialysis machine was the test machine,and the Fresenius 4008 series hemodialysis machine was as the control machine,indicators of blood routine test,serum electrolytes,liver and kidney function test,blood gas analysis,CRP were compared,body weight before and after hemodialysis,ultrafiltration volume were recorded,urea clearance index,urea reduction ratio were calculated.The XL90 conductivity meter was connected in series in the test machine,to monitor the temperature,conductance,venous pressure and arterial pressure during the dialysis in real time,and the measured value were compared with the machine monitoring value.Results Both of the test machine and the control machine could effectively eliminate creatinine,urea nitrogen and other uremic toxins,could continuously supply qualified dialysate,and precisely control the ultrafiltration volume.There were no significant differences in temperature,conductance,venous pressure and arterial pressure monitoring with the real time measured value by XL90 conductivity meter.Conclusions OBERS-3000 multifunctional hemodialysis machine can effectively eliminate uremic toxins,maintain electrolyte and acid-base balance,and can accurately display the monitoring parameters.

    2017年S1期 1-6页 [查看摘要][在线阅读][下载 366K]
    [下载次数:8 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Efficacy and Safety of Febuxost at in the Treatment of Chronic Kidney Disease with Hyperuricemia: A Meta- Analysis

    Jingyun Ou;Bin Yan;Shenling Huang;Mingming Ma;Jun Ke;Hongwei Hu;Sibo Huang;Xiangnan Dong;Aiyun Cha;Zuhui Chen;Yu Mong;Fanna Liu;W.Pommer;Chen Yun;Yongpin Lu;Shufei Zeng;Lianghong Yin;B.Hocher;

    Background Febuxostat and allopurinol have different pharmacological mechanisms,the efficacy of febuxostat in chronic kidney disease complicated with hyperuricemia remains controversial.A meta-analysis and systemic review was conducted to investigate the efficacy and safety of febuxostat in CKD populations complicated with hyperuricemia.Methods A comprehensive search was conducted in multiple electronic databases based on the inclusion and exclusion criteria,before December 2016,searching for the published studies,including Chinese and English,relating to the use of febuxostat in CKD populations complicated with hyperuricemia,and manual retrieval of the inclusion literature.Literature evaluation and data extraction were performed by two reviewers,Rev Man 5.3 was used to perform the meta-analysis.Results Seven studies with 482 CKD patients were included in the meta-analysis.We found that febuxostat can significantly slow the decreasing speed of e GFR[RR=4.90,95%CI(1.95,7.84),P=0.001],and reduce serum uric acid[RR=-99.30,95%CI(-172.24,-26.37),P=0.008]levels in CKD patients complicated with hyperuricemia when compairing with control group.There was no significant difference in the levels of systolic blood pressure[RR=-2.19,95%CI(-9.99,5.61),P=0.58],diastolic blood pressure[RR=-2.30,95%CI(-7.33,2.73),P=0.10],low density lipoprotein[RR=-0.47,95%CI(-7.64,6.69),P=0.90]between the two groups.Compared with the control group,the use of febuxostat increase the incidence of adverse reaction[RR=4.73,95%CI(1.04,21.43),P=0.04]in patients.Conclusions Febuxostat can significantly lower serum uric acid level and effectively delay the process of chronic renal failure in CKD patients complicated with hyperuricemic,increases the incidence of adverse reaction,no significant difference in SBP,DBP,LDL,when compared with control group.

    2017年S1期 7-12页 [查看摘要][在线阅读][下载 2755K]
    [下载次数:21 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Efficacy and Safety of Febuxost at in the Treatment of Chronic Kidney Disease with Hyperuricemia: A Meta- Analysis

    Jingyun Ou;Bin Yan;Shenling Huang;Mingming Ma;Jun Ke;Hongwei Hu;Sibo Huang;Xiangnan Dong;Aiyun Cha;Zuhui Chen;Yu Mong;Fanna Liu;W.Pommer;Chen Yun;Yongpin Lu;Shufei Zeng;Lianghong Yin;B.Hocher;

    Background Febuxostat and allopurinol have different pharmacological mechanisms,the efficacy of febuxostat in chronic kidney disease complicated with hyperuricemia remains controversial.A meta-analysis and systemic review was conducted to investigate the efficacy and safety of febuxostat in CKD populations complicated with hyperuricemia.Methods A comprehensive search was conducted in multiple electronic databases based on the inclusion and exclusion criteria,before December 2016,searching for the published studies,including Chinese and English,relating to the use of febuxostat in CKD populations complicated with hyperuricemia,and manual retrieval of the inclusion literature.Literature evaluation and data extraction were performed by two reviewers,Rev Man 5.3 was used to perform the meta-analysis.Results Seven studies with 482 CKD patients were included in the meta-analysis.We found that febuxostat can significantly slow the decreasing speed of e GFR[RR=4.90,95%CI(1.95,7.84),P=0.001],and reduce serum uric acid[RR=-99.30,95%CI(-172.24,-26.37),P=0.008]levels in CKD patients complicated with hyperuricemia when compairing with control group.There was no significant difference in the levels of systolic blood pressure[RR=-2.19,95%CI(-9.99,5.61),P=0.58],diastolic blood pressure[RR=-2.30,95%CI(-7.33,2.73),P=0.10],low density lipoprotein[RR=-0.47,95%CI(-7.64,6.69),P=0.90]between the two groups.Compared with the control group,the use of febuxostat increase the incidence of adverse reaction[RR=4.73,95%CI(1.04,21.43),P=0.04]in patients.Conclusions Febuxostat can significantly lower serum uric acid level and effectively delay the process of chronic renal failure in CKD patients complicated with hyperuricemic,increases the incidence of adverse reaction,no significant difference in SBP,DBP,LDL,when compared with control group.

    2017年S1期 7-12页 [查看摘要][在线阅读][下载 2755K]
    [下载次数:21 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Experimental Design and Clinical Observation of Modialysis Apparatus

    Yunyi Li;Zongchao Yu;Sibo Huang;Mingming Ma;Huanhuan Liu;Taksui Wong;Fanna Liu;Huifeng Song;Chen Yun;Hongwei Hu;Yu Chen;Fanna Liu;Yongpin Lu;Huanhuan Liu;Aiyun Cha;Guanmin Wu;Jie Shu;Gangyi Chen;Shuifu Tang;Lianghong Yin;

    Objective To evaluate the clinical safety and efficacy of polyethersulfone membrane hollow fiber dialyzer Enttex~(TM)-16LF(E60)in treating patients with end stage renal disease caused by a variety of reasons.Methods This clinical trialwas designed as a randomized,open,two-phase crossover and positive control,non-inferiority study.To evaluate the indicators of blood routine test,serum biochemical indexes,blood gas analysis,vital signsbefore and after hemodialysis,and the adverse events were recorded indetail.Results There was no significant difference in creatinine,urea,creatinine clearance and electrolytes between Enttex TM-16LF dialyzer and control dialyzer before and after hemodialysis,no adverse event associated with the Enttex~(TM)-16LF dialyzer was found during the study.Conclusions The Enttex~(TM)-16LF dialyzeris effective and safe for hemodialysis in patients with end stage renal disease.

    2017年S1期 13-16页 [查看摘要][在线阅读][下载 274K]
    [下载次数:5 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Experimental Design and Clinical Observation of Modialysis Apparatus

    Yunyi Li;Zongchao Yu;Sibo Huang;Mingming Ma;Huanhuan Liu;Taksui Wong;Fanna Liu;Huifeng Song;Chen Yun;Hongwei Hu;Yu Chen;Fanna Liu;Yongpin Lu;Huanhuan Liu;Aiyun Cha;Guanmin Wu;Jie Shu;Gangyi Chen;Shuifu Tang;Lianghong Yin;

    Objective To evaluate the clinical safety and efficacy of polyethersulfone membrane hollow fiber dialyzer Enttex~(TM)-16LF(E60)in treating patients with end stage renal disease caused by a variety of reasons.Methods This clinical trialwas designed as a randomized,open,two-phase crossover and positive control,non-inferiority study.To evaluate the indicators of blood routine test,serum biochemical indexes,blood gas analysis,vital signsbefore and after hemodialysis,and the adverse events were recorded indetail.Results There was no significant difference in creatinine,urea,creatinine clearance and electrolytes between Enttex TM-16LF dialyzer and control dialyzer before and after hemodialysis,no adverse event associated with the Enttex~(TM)-16LF dialyzer was found during the study.Conclusions The Enttex~(TM)-16LF dialyzeris effective and safe for hemodialysis in patients with end stage renal disease.

    2017年S1期 13-16页 [查看摘要][在线阅读][下载 274K]
    [下载次数:5 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 国产OBERS-3000血液透析机原理及创新设计

    尹良红;云琛;管保章;马明明;董向楠;刘璠娜;杨佩钿;伍冠敏;胡波;刘潼;罗丽花;陈祖辉;郑慧渊;

    <正>进入21世纪以来,慢性肾功能衰竭已成为世界范围内继心脑血管疾病、肿瘤和糖尿病后严重威胁人类健康的一大公害。慢性肾衰竭是所有肾脏疾病和一些老年人及全身慢性疾病的最终结果。据统计目前全世界罹患终末期肾病的人群已超过2百万人口,中国有约4 000余万各种肾脏病患者,加之老年人肾脏的退性变,每年新发生慢性肾衰竭者为10~30万。血液透析是一种血液净化疗法,虽然尚不能实现肾脏自我平衡、调节、代谢和内分泌等功能,但能替代肾脏的部分排泄功能,使终末期肾脏病患者的存活率及生活质量直线提高,是治疗急慢性肾功能衰竭最有效的措施之一[1]。现在应用在我国临床上的大部分都是进口产品,国内产品只有进行核心部件和关键技术创新,

    2017年S1期 17-19页 [查看摘要][在线阅读][下载 740K]
    [下载次数:142 ] |[网刊下载次数:0 ] |[引用频次:5 ] |[阅读次数:0 ]
  • 国产OBERS-3000血液透析机原理及创新设计

    尹良红;云琛;管保章;马明明;董向楠;刘璠娜;杨佩钿;伍冠敏;胡波;刘潼;罗丽花;陈祖辉;郑慧渊;

    <正>进入21世纪以来,慢性肾功能衰竭已成为世界范围内继心脑血管疾病、肿瘤和糖尿病后严重威胁人类健康的一大公害。慢性肾衰竭是所有肾脏疾病和一些老年人及全身慢性疾病的最终结果。据统计目前全世界罹患终末期肾病的人群已超过2百万人口,中国有约4 000余万各种肾脏病患者,加之老年人肾脏的退性变,每年新发生慢性肾衰竭者为10~30万。血液透析是一种血液净化疗法,虽然尚不能实现肾脏自我平衡、调节、代谢和内分泌等功能,但能替代肾脏的部分排泄功能,使终末期肾脏病患者的存活率及生活质量直线提高,是治疗急慢性肾功能衰竭最有效的措施之一[1]。现在应用在我国临床上的大部分都是进口产品,国内产品只有进行核心部件和关键技术创新,

    2017年S1期 17-19页 [查看摘要][在线阅读][下载 740K]
    [下载次数:142 ] |[网刊下载次数:0 ] |[引用频次:5 ] |[阅读次数:0 ]
  • 贵州及广州两血透中心患者CKD-MBD的特点及差异分析

    黄三义;何大兴;邓继鸿;党筱妍;苏宁;

    目的研究贵州及广州两血透中心维持性血透患者CKD-MBD的特点,并分析造成其差异的可能原因。方法收集2016年7月1日至2016年10月1日在中山大学附属第六医院(广州中心)及贵州省镇宁县人民医院(贵州中心)规律血透患者共57例,其中贵州中心25例,广州中心32例。分别记录其基本人口学资料、血管通路、抗凝剂、Kt/V、血钙、血磷、血PTH、血白蛋白、血碱性磷酸酶等指标,比较双中心血透患者上述指标的差别。结果两中心血透患者在年龄、性别、基础肾脏病、内瘘比例、抗凝剂、透析龄方面无差别。贵州中心校正钙(1.87±0.17 mmol/L vs 2.28±0.19 mmol/L,P<0.001)及血磷水平(1.45±0.49 mmol/L vs 2.19±0.66 mmol/L,P<0.001)低于广州中心;低钙血症比例高于广州中心(100%vs 12.5%,P<0.001),而广州中心高磷血症比例高于贵州中心(78.1%vs 20.0%,P<0.001),双中心在继发性甲旁亢发病率方面无差别(53.1%vs 68.0%,P=0.289)。结论高磷血症是广州中心血透患者CKD-MBD的主要特点,而低钙血症是贵州中心血透患者CKD-MBD的主要特点,上述钙磷代谢紊乱导致两中心继发性甲旁亢高发。

    2017年S1期 20-22页 [查看摘要][在线阅读][下载 271K]
    [下载次数:63 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 贵州及广州两血透中心患者CKD-MBD的特点及差异分析

    黄三义;何大兴;邓继鸿;党筱妍;苏宁;

    目的研究贵州及广州两血透中心维持性血透患者CKD-MBD的特点,并分析造成其差异的可能原因。方法收集2016年7月1日至2016年10月1日在中山大学附属第六医院(广州中心)及贵州省镇宁县人民医院(贵州中心)规律血透患者共57例,其中贵州中心25例,广州中心32例。分别记录其基本人口学资料、血管通路、抗凝剂、Kt/V、血钙、血磷、血PTH、血白蛋白、血碱性磷酸酶等指标,比较双中心血透患者上述指标的差别。结果两中心血透患者在年龄、性别、基础肾脏病、内瘘比例、抗凝剂、透析龄方面无差别。贵州中心校正钙(1.87±0.17 mmol/L vs 2.28±0.19 mmol/L,P<0.001)及血磷水平(1.45±0.49 mmol/L vs 2.19±0.66 mmol/L,P<0.001)低于广州中心;低钙血症比例高于广州中心(100%vs 12.5%,P<0.001),而广州中心高磷血症比例高于贵州中心(78.1%vs 20.0%,P<0.001),双中心在继发性甲旁亢发病率方面无差别(53.1%vs 68.0%,P=0.289)。结论高磷血症是广州中心血透患者CKD-MBD的主要特点,而低钙血症是贵州中心血透患者CKD-MBD的主要特点,上述钙磷代谢紊乱导致两中心继发性甲旁亢高发。

    2017年S1期 20-22页 [查看摘要][在线阅读][下载 271K]
    [下载次数:63 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • IgA肾病单纯性血尿患者肾脏病理分级与临床的关系

    刘欢欢;尹良红;刘璠娜;黄盛玲;陈昕;

    目的分析Ig A肾病单纯性血尿患者牛津病理分级与血尿及肾功能的关系,为Ig A肾病单纯性血尿患者的治疗提供理论依据。方法横断面分析我院84例经肾活检确诊为原发性Ig A肾病单纯性血尿患者的病理及临床资料。结果 84例Ig A肾病单纯性血尿患者中仅有4例发现时双肾肾小球滤过率<60ml/min。病理表现发生肾小球球性硬化的占60.71%,35例(41.67%)出现肾小球节段硬化;发生肾小球全球和(或)节段硬化的病例数占64.28%。肾小球球性和/或节段硬化比例主要集中在30%以内。根据Ig A肾病牛津分级标准,M1、S1、E1、T1和T2及C1的发生率分别为69%、41.7%、10.7%、27.3%及25%。血尿严重程度与毛细血管内细胞增多有关(P<0.05),与肾功能损伤无明显关系。小管萎缩及间质纤维化的程度与病程长短明显相关(P=0.02),且其严重程度直接影响肾功能水平(P<0.01)。结论 Ig A肾病单纯性血尿患者临床损伤轻微,但肾脏病理损伤不一定轻,小管萎缩/间质纤维化程度与肾功能损伤明显相关。

    2017年S1期 23-27页 [查看摘要][在线阅读][下载 405K]
    [下载次数:169 ] |[网刊下载次数:0 ] |[引用频次:2 ] |[阅读次数:0 ]
  • IgA肾病单纯性血尿患者肾脏病理分级与临床的关系

    刘欢欢;尹良红;刘璠娜;黄盛玲;陈昕;

    目的分析Ig A肾病单纯性血尿患者牛津病理分级与血尿及肾功能的关系,为Ig A肾病单纯性血尿患者的治疗提供理论依据。方法横断面分析我院84例经肾活检确诊为原发性Ig A肾病单纯性血尿患者的病理及临床资料。结果 84例Ig A肾病单纯性血尿患者中仅有4例发现时双肾肾小球滤过率<60ml/min。病理表现发生肾小球球性硬化的占60.71%,35例(41.67%)出现肾小球节段硬化;发生肾小球全球和(或)节段硬化的病例数占64.28%。肾小球球性和/或节段硬化比例主要集中在30%以内。根据Ig A肾病牛津分级标准,M1、S1、E1、T1和T2及C1的发生率分别为69%、41.7%、10.7%、27.3%及25%。血尿严重程度与毛细血管内细胞增多有关(P<0.05),与肾功能损伤无明显关系。小管萎缩及间质纤维化的程度与病程长短明显相关(P=0.02),且其严重程度直接影响肾功能水平(P<0.01)。结论 Ig A肾病单纯性血尿患者临床损伤轻微,但肾脏病理损伤不一定轻,小管萎缩/间质纤维化程度与肾功能损伤明显相关。

    2017年S1期 23-27页 [查看摘要][在线阅读][下载 405K]
    [下载次数:169 ] |[网刊下载次数:0 ] |[引用频次:2 ] |[阅读次数:0 ]

摘要

  • 超声引导下经皮腔内血管成形术治疗动静脉内瘘狭窄术后通畅率的影响因素分析

    黄盛玲;胡波;刘璠娜;孟宇;尹良红;

    目的经皮腔内血管成形术(percutaneous coronary angioplasty,PTA)是治疗动静脉内瘘狭窄的主要方法 ,本研究探讨影响超声引导下PTA治疗后内瘘一期通畅率的因素。方法选取因动静脉内瘘狭窄接受超声引导下PTA治疗的维持性血液透析(maintenance hemodialysis,MHD)患者32例,选择可能对超声引导下PTA治疗后内瘘一期通畅率有影响的因素,包括年龄、性别、糖尿病、冠心病、透析龄、AVF使用时间、狭窄侧、狭窄数量、狭窄程度、狭窄部位的长度等变量,应用Kaplan-Meier法比较不同组间的通畅率差异,应用Cox回归分析影响PTA治疗后内瘘一期通畅率的相关因素。结果 (1)血液透析患者在超声引导下PTA治疗后3月、6月、12月动静脉内瘘一期通畅率分别为96.7%、86.7%和65.5%,中位通畅时间为16.00±4.27月。(2)30例患者经单因素Kaplan-meier分析,发现在年龄、糖尿病、AVF使用时间、内瘘狭窄长度因素中各组的通畅率差异有统计学意义(P<0.05)。COX多元回归分析提示患者年龄可能是超声引导下PTA治疗后内瘘一期通畅率的独立影响因素(RR=1.125,P=0.010)。结论年龄、糖尿病、AVF使用时间、狭窄长度可能是超声引导下PTA治疗后内瘘一期通畅率的影响因素。

    2017年S1期 16页 [查看摘要][在线阅读][下载 106K]
    [下载次数:267 ] |[网刊下载次数:0 ] |[引用频次:3 ] |[阅读次数:0 ]
  • 超声引导下经皮腔内血管成形术治疗动静脉内瘘狭窄术后通畅率的影响因素分析

    黄盛玲;胡波;刘璠娜;孟宇;尹良红;

    目的经皮腔内血管成形术(percutaneous coronary angioplasty,PTA)是治疗动静脉内瘘狭窄的主要方法 ,本研究探讨影响超声引导下PTA治疗后内瘘一期通畅率的因素。方法选取因动静脉内瘘狭窄接受超声引导下PTA治疗的维持性血液透析(maintenance hemodialysis,MHD)患者32例,选择可能对超声引导下PTA治疗后内瘘一期通畅率有影响的因素,包括年龄、性别、糖尿病、冠心病、透析龄、AVF使用时间、狭窄侧、狭窄数量、狭窄程度、狭窄部位的长度等变量,应用Kaplan-Meier法比较不同组间的通畅率差异,应用Cox回归分析影响PTA治疗后内瘘一期通畅率的相关因素。结果 (1)血液透析患者在超声引导下PTA治疗后3月、6月、12月动静脉内瘘一期通畅率分别为96.7%、86.7%和65.5%,中位通畅时间为16.00±4.27月。(2)30例患者经单因素Kaplan-meier分析,发现在年龄、糖尿病、AVF使用时间、内瘘狭窄长度因素中各组的通畅率差异有统计学意义(P<0.05)。COX多元回归分析提示患者年龄可能是超声引导下PTA治疗后内瘘一期通畅率的独立影响因素(RR=1.125,P=0.010)。结论年龄、糖尿病、AVF使用时间、狭窄长度可能是超声引导下PTA治疗后内瘘一期通畅率的影响因素。

    2017年S1期 16页 [查看摘要][在线阅读][下载 106K]
    [下载次数:267 ] |[网刊下载次数:0 ] |[引用频次:3 ] |[阅读次数:0 ]
  • 肾衰患者肾纤维化发展的关键候选基因和通路的生物信息学分析

    陈小依;罗婷;马明明;尹良红;

    目的肾脏纤维化是各种原发或继发性肾脏病持续进展,导致正常肾脏组织结构被细胞外基质所取代,伴肾功能进行性不可逆性损害的病理过程,是引起终末期肾衰竭的主要原因和病理基础之一。ESRD患者需要接受RRT以延长生命,消耗大量医学资源。近年来对肾脏纤维化机制的有关研究很多,但涉及的信号通路和驱动基因在很大程度上还不清楚。利用生物信息学方法分析影响肾脏纤维化发病的关键基因和通路,为进一步动物实验研究其功能和参与的调控机制提供一定的理论依据。方法在公共基因芯片数据库(GEO)中下载肾脏纤维化相关基因表达谱数据(GSE66494)。该芯片包括53例肾脏纤维化患者组织样本及8例正常人肾脏组织。我们利用GEO2R工具对肾纤维化患者组织与正常组织中表达的基因进行差异分析,并利用DAVID工具对差异表达基因进行功能和通路富集分析(GO、KEGG)。我们还通过生物信息学工具STRING v10.5构建差异基因的蛋白质-蛋白质相互作用网络,并利用Cytoscape对蛋白质互作网络进行可视化并筛选核心基因。结果通过对53例肾纤维化组织与正常组织基因表达谱数据进行差异分析,我们从GSE66494数据集中共筛选出514个差异表达的基因,其中138个在肾纤维化组织中上调,376个在肾纤维化组织中下调。GO分析结果显示,差异表达基因主要富集在细胞外组成成分,急性期反应以及物质运输相关生物学过程等。KEGG结果显示差异表达的基因参与调控的显著的信号通路主要包括:胰腺分泌,蛋白质的消化和吸收,非洲锥虫病,PPAR信号通路,PI3K-Akt信号通路以及疟疾通路。通过构建差异表达基因的蛋白质-蛋白质相互作用网络,我们从差异表达基因中筛选出了10个核心基因包括ALB,TOP2A,MYC,FOS,PLG,IL10,CCNB2,REN,PTGS2,TAC1。结论我们通过生物信息学方法发现了在正常组织与肾纤维化组织中差异表达的514个基因,并发现了其调控的重要的信号通路。以上这些差异基因尤其是核心基因,和信号通路,可能是参与肾纤维化发生,发展的关键基因和通路,这为肾脏纤维化的诊断和治疗提供了新的思路或新靶点。

    2017年S1期 19页 [查看摘要][在线阅读][下载 94K]
    [下载次数:348 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 肾衰患者肾纤维化发展的关键候选基因和通路的生物信息学分析

    陈小依;罗婷;马明明;尹良红;

    目的肾脏纤维化是各种原发或继发性肾脏病持续进展,导致正常肾脏组织结构被细胞外基质所取代,伴肾功能进行性不可逆性损害的病理过程,是引起终末期肾衰竭的主要原因和病理基础之一。ESRD患者需要接受RRT以延长生命,消耗大量医学资源。近年来对肾脏纤维化机制的有关研究很多,但涉及的信号通路和驱动基因在很大程度上还不清楚。利用生物信息学方法分析影响肾脏纤维化发病的关键基因和通路,为进一步动物实验研究其功能和参与的调控机制提供一定的理论依据。方法在公共基因芯片数据库(GEO)中下载肾脏纤维化相关基因表达谱数据(GSE66494)。该芯片包括53例肾脏纤维化患者组织样本及8例正常人肾脏组织。我们利用GEO2R工具对肾纤维化患者组织与正常组织中表达的基因进行差异分析,并利用DAVID工具对差异表达基因进行功能和通路富集分析(GO、KEGG)。我们还通过生物信息学工具STRING v10.5构建差异基因的蛋白质-蛋白质相互作用网络,并利用Cytoscape对蛋白质互作网络进行可视化并筛选核心基因。结果通过对53例肾纤维化组织与正常组织基因表达谱数据进行差异分析,我们从GSE66494数据集中共筛选出514个差异表达的基因,其中138个在肾纤维化组织中上调,376个在肾纤维化组织中下调。GO分析结果显示,差异表达基因主要富集在细胞外组成成分,急性期反应以及物质运输相关生物学过程等。KEGG结果显示差异表达的基因参与调控的显著的信号通路主要包括:胰腺分泌,蛋白质的消化和吸收,非洲锥虫病,PPAR信号通路,PI3K-Akt信号通路以及疟疾通路。通过构建差异表达基因的蛋白质-蛋白质相互作用网络,我们从差异表达基因中筛选出了10个核心基因包括ALB,TOP2A,MYC,FOS,PLG,IL10,CCNB2,REN,PTGS2,TAC1。结论我们通过生物信息学方法发现了在正常组织与肾纤维化组织中差异表达的514个基因,并发现了其调控的重要的信号通路。以上这些差异基因尤其是核心基因,和信号通路,可能是参与肾纤维化发生,发展的关键基因和通路,这为肾脏纤维化的诊断和治疗提供了新的思路或新靶点。

    2017年S1期 19页 [查看摘要][在线阅读][下载 94K]
    [下载次数:348 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 狼疮肾炎的的诊治进展

    钟莉娴;江思敏;彭稚媚;刘璠娜;

    狼疮肾炎是影响系统性红斑狼疮预后的重要因素,包括肾小球和肾间质病变的炎症性疾病,其病程容易反复且迁延,给治疗带来了一定的难度。根据国际肾脏病学会/肾脏病理学会LN的分类标准,可将LN分为以下几类:Ι型微小病变型狼疮肾炎,Ⅱ型系膜增生型狼疮肾炎,Ⅲ局灶增生型肾小球肾炎,Ⅳ弥漫增生型狼疮肾炎,Ⅴ膜型狼疮肾炎,Ⅵ硬化型狼疮肾炎。治疗上,在过去,糖皮质激素、环磷酰胺在LN上运用广泛,较为局限;近年来,免疫吸附受到重视,有研究表明免疫吸附疗法联合激素和CTX治疗优于单纯激素和CTX治疗;此外生物制剂也较前运用得多,其中有荟萃分析表明利妥昔单抗在103例狼疮肾炎患者中达到的缓解率为91%,但由于受到价格等因素的影响,生物制剂在国外应用较多,国内运用较少;除外还有硫唑嘌呤、来氟米特等药物对狼疮肾炎也有一定的疗效。

    2017年S1期 22页 [查看摘要][在线阅读][下载 95K]
    [下载次数:373 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • 狼疮肾炎的的诊治进展

    钟莉娴;江思敏;彭稚媚;刘璠娜;

    狼疮肾炎是影响系统性红斑狼疮预后的重要因素,包括肾小球和肾间质病变的炎症性疾病,其病程容易反复且迁延,给治疗带来了一定的难度。根据国际肾脏病学会/肾脏病理学会LN的分类标准,可将LN分为以下几类:Ι型微小病变型狼疮肾炎,Ⅱ型系膜增生型狼疮肾炎,Ⅲ局灶增生型肾小球肾炎,Ⅳ弥漫增生型狼疮肾炎,Ⅴ膜型狼疮肾炎,Ⅵ硬化型狼疮肾炎。治疗上,在过去,糖皮质激素、环磷酰胺在LN上运用广泛,较为局限;近年来,免疫吸附受到重视,有研究表明免疫吸附疗法联合激素和CTX治疗优于单纯激素和CTX治疗;此外生物制剂也较前运用得多,其中有荟萃分析表明利妥昔单抗在103例狼疮肾炎患者中达到的缓解率为91%,但由于受到价格等因素的影响,生物制剂在国外应用较多,国内运用较少;除外还有硫唑嘌呤、来氟米特等药物对狼疮肾炎也有一定的疗效。

    2017年S1期 22页 [查看摘要][在线阅读][下载 95K]
    [下载次数:373 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • Correlation between Vascular Calcification and Serum Sclerostin in MHD Patients

    Yangyang Zhang;Shufei Zeng;Chen Yun;Lifeng Yang;Fanna Liu;Guanmin Wu;Taksui Wong;Bo Hu;Xiangnan Dong;Folan Li;Yu Chen;Peitian Yang;Aiyun Cha;Huanhuan Liu;Mingming Ma;B.Hocher;W. Pommer;Huiyuan Zheng;Tong Liu;Zuhui Chen;Lianghong Yin;

    Objective Investigate the correlation between serum sclerostinlevel and chronic kidney disease-mineral and bone disorder(CKD-MBD),especially vascular calcification,in maintenance hemodialysis(MHD)patients.Methods This is across-sectional study,a total of 72 MHD patients were included from the first affiliated hospital of Jinan university.Measure the biochemical indicators of mineral metabolism,renal function,and serum sclerostin level by ELISA.The abdominal aorta calcification score(AACS)was assessed according to Kauppila method on lateral spine imaging using DEXA.Patients were distributed into two groups according to the level of serum sclerostin:low sclerostingroup(≤125 pg/ml)and high sclerostingroup(>125 pg/ml).Analyze the association of serum sclerostin level with the indicators of CKD-MBD.Results There was significant difference in i PTH level between high sclerost in group and low sclerost in group.Multivariate Logistic regression analysis demonstrated that dialysis duration,male and anuria were independent risk factor of high sclerostin level,and i PTH and Kt/V were protective factors.Conclusion Dialysis duration,man,anuria was independent risk factors and i PTH,Kt/V were protective factors of high serum sclerostin level in MHD patients.There was no correlation between abdominal aorta calcification and serum sclerostin level.

    2017年S1期 27页 [查看摘要][在线阅读][下载 96K]
    [下载次数:5 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Correlation between Vascular Calcification and Serum Sclerostin in MHD Patients

    Yangyang Zhang;Shufei Zeng;Chen Yun;Lifeng Yang;Fanna Liu;Guanmin Wu;Taksui Wong;Bo Hu;Xiangnan Dong;Folan Li;Yu Chen;Peitian Yang;Aiyun Cha;Huanhuan Liu;Mingming Ma;B.Hocher;W. Pommer;Huiyuan Zheng;Tong Liu;Zuhui Chen;Lianghong Yin;

    Objective Investigate the correlation between serum sclerostinlevel and chronic kidney disease-mineral and bone disorder(CKD-MBD),especially vascular calcification,in maintenance hemodialysis(MHD)patients.Methods This is across-sectional study,a total of 72 MHD patients were included from the first affiliated hospital of Jinan university.Measure the biochemical indicators of mineral metabolism,renal function,and serum sclerostin level by ELISA.The abdominal aorta calcification score(AACS)was assessed according to Kauppila method on lateral spine imaging using DEXA.Patients were distributed into two groups according to the level of serum sclerostin:low sclerostingroup(≤125 pg/ml)and high sclerostingroup(>125 pg/ml).Analyze the association of serum sclerostin level with the indicators of CKD-MBD.Results There was significant difference in i PTH level between high sclerost in group and low sclerost in group.Multivariate Logistic regression analysis demonstrated that dialysis duration,male and anuria were independent risk factor of high sclerostin level,and i PTH and Kt/V were protective factors.Conclusion Dialysis duration,man,anuria was independent risk factors and i PTH,Kt/V were protective factors of high serum sclerostin level in MHD patients.There was no correlation between abdominal aorta calcification and serum sclerostin level.

    2017年S1期 27页 [查看摘要][在线阅读][下载 96K]
    [下载次数:5 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 他汀类药物对急性肾损伤预后的影响

    江思敏;彭稚媚;刘璠娜;孟宇;尹良红;

    目的住院病人急性肾损伤(AKI)的发病率在不断增长中,幸存者的心血管事件和死亡的风险也很高。与没有发生AKI的患者相比,在住院期间发生过AKI的终末期肾病患者,在此后2年内死亡的风险增加40%,患心血管疾病的风险增加50%到60%。目前还没有可以改善AKI的长期预后的有效策略。但是发现和治疗AKI后发生的CKD可能会改善患者的预后。方法加拿大卫生研究所有一个2008年至2011年期间进行的一项回顾性队列研究,其中所有受试者最低随访时间为2年。参与者为在住院期间发生过AKI,并在出院后患有慢性肾病的大于18岁的成人(平均年龄69.9岁,平均出院后肾小球滤过率(e GFR)43.0 ml/min/1.73 m~2)他们AKI的定义是7天内血清肌酐增加大于或等于50%或在48小时内血肌酐增加26.5μmol/L和/或住院7天内要求急性透析的。出院后CKD的定义为e GFR<60 ml/min/1.73 m~2,ACR>30 mg/g,PCR>150 mg/g大于90天。结果在总共53 700人的随访中,出院后使用他汀类药物治疗的患者有更低的死亡风险和再次住院的风险。与没有使用他汀类药物比,在出院后服用了他汀类药物或继续服用之前的他汀类药物的患者均有更低的全因住院治疗率,但是并没有明显的降低患者心血管疾病的风险。但是在此研究中,只有39.1%的在住院期间发生过AKI并在出院后患有慢性肾病的患者,在出院后的两年使用了他汀类药物治疗,尽管他们患心血管疾病的风险高,尽管国际指导方针CKD脂质管理建议成年人>50岁e GFR<60 ml/min/1.73m~2应该接受他汀类药物

    2017年S1期 36页 [查看摘要][在线阅读][下载 91K]
    [下载次数:93 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 他汀类药物对急性肾损伤预后的影响

    江思敏;彭稚媚;刘璠娜;孟宇;尹良红;

    目的住院病人急性肾损伤(AKI)的发病率在不断增长中,幸存者的心血管事件和死亡的风险也很高。与没有发生AKI的患者相比,在住院期间发生过AKI的终末期肾病患者,在此后2年内死亡的风险增加40%,患心血管疾病的风险增加50%到60%。目前还没有可以改善AKI的长期预后的有效策略。但是发现和治疗AKI后发生的CKD可能会改善患者的预后。方法加拿大卫生研究所有一个2008年至2011年期间进行的一项回顾性队列研究,其中所有受试者最低随访时间为2年。参与者为在住院期间发生过AKI,并在出院后患有慢性肾病的大于18岁的成人(平均年龄69.9岁,平均出院后肾小球滤过率(e GFR)43.0 ml/min/1.73 m~2)他们AKI的定义是7天内血清肌酐增加大于或等于50%或在48小时内血肌酐增加26.5μmol/L和/或住院7天内要求急性透析的。出院后CKD的定义为e GFR<60 ml/min/1.73 m~2,ACR>30 mg/g,PCR>150 mg/g大于90天。结果在总共53 700人的随访中,出院后使用他汀类药物治疗的患者有更低的死亡风险和再次住院的风险。与没有使用他汀类药物比,在出院后服用了他汀类药物或继续服用之前的他汀类药物的患者均有更低的全因住院治疗率,但是并没有明显的降低患者心血管疾病的风险。但是在此研究中,只有39.1%的在住院期间发生过AKI并在出院后患有慢性肾病的患者,在出院后的两年使用了他汀类药物治疗,尽管他们患心血管疾病的风险高,尽管国际指导方针CKD脂质管理建议成年人>50岁e GFR<60 ml/min/1.73m~2应该接受他汀类药物

    2017年S1期 36页 [查看摘要][在线阅读][下载 91K]
    [下载次数:93 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 溶血性尿毒症综合征(HUS)和血栓性血小板减少性紫癜(TTP)治疗的临床实践

    姚丽荣;刘璠娜;尹良红;

    <正>溶血性尿毒症综合征(HUS)是一类原因不明的急性血管内溶血性贫血伴肾功能衰竭的综合征。可累及多系统,以微血管病性溶血、急性肾衰竭和血小板减少为主要特征,由于HUS与血栓性血小板减少性紫癜(TTP)在病因、发病机制和临床表现方面均有共同之处,越来越多的学者认为两者是同一疾病不同阶段的临床表现,可统称之为HUS/TTP或血栓性微血管病(TMA)。TMA病理上可见肾小球及血管内皮损伤,内皮细胞的损伤可能是导致TMA的事件中的因素之一。溶血尿毒综合征(HUS)病例

    2017年S1期 41页 [查看摘要][在线阅读][下载 87K]
    [下载次数:490 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 溶血性尿毒症综合征(HUS)和血栓性血小板减少性紫癜(TTP)治疗的临床实践

    姚丽荣;刘璠娜;尹良红;

    <正>溶血性尿毒症综合征(HUS)是一类原因不明的急性血管内溶血性贫血伴肾功能衰竭的综合征。可累及多系统,以微血管病性溶血、急性肾衰竭和血小板减少为主要特征,由于HUS与血栓性血小板减少性紫癜(TTP)在病因、发病机制和临床表现方面均有共同之处,越来越多的学者认为两者是同一疾病不同阶段的临床表现,可统称之为HUS/TTP或血栓性微血管病(TMA)。TMA病理上可见肾小球及血管内皮损伤,内皮细胞的损伤可能是导致TMA的事件中的因素之一。溶血尿毒综合征(HUS)病例

    2017年S1期 41页 [查看摘要][在线阅读][下载 87K]
    [下载次数:490 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Micro-RNAs Regulate Metabolic Syndrome-induced Senescence in Adipose Tissue-derived Mesenchymal Stem Cells of through P16/MAPK Pathway

    Yu Meng;Alfonso Eirin;Lilach O.Lerman;

    Background Mesenchymal stem cells(MSC)constitute an important repair system,but may be impaired by exposure to cardiovascular risk factors.Consequently,adipose tissue-derived MSCs from pigs with the metabolic syndrome(Met S)show decreased vitality.A growing number of micro RNAs(mi RNAs)are recognized as key modulators of senescence,but their role in regulating senescence in MSC in Mets is unclear.We tested the hypothesis that Met S upregulates in MSC expression of mi RNAs that can serve as post-transcriptional regulators of senescence-associated(SA)genes.Methods MSCs were collected from swine abdominal adipose tissue after 16 weeks of Lean or Obese diet(n=6 each).Next-generation mi RNA sequencing(mi RNA-seq)was performed to identify mi RNAs up-or down-regulated in Met S-MSC compare to Lean-MSCs.Functional pathway analysis of SA genes targeted by mi RNAs was performed using gene ontology analysis.MSC senescence was evaluated by p16 and p21 immunoreactivity,H2AX protein expression,and SA-beta-Galactosidase activity.In addition,gene expression of p16,p21,MAPK3,and MAPK14 was studied after inhibition of SA-mi R-27b.Results Senescence biomarkers were significantly elevated in Met S MSC.We found the 7 upregulated mi RNAs,including mi R-27b,and 3 downregulated mi RNAs in Met S-MSCs,which regulate 35 SA genes,particularly MAPK signaling.Inhibition of mi R-27b in cultured MSC downregulated p16 and MARP3 genes.Conclusions Met S modulate MSC expression of SA-mi RNAs that may play the role in modulating their senescence,and the p16 pathway in Met S-MSCs senescence is the primary pathway.

    2017年S1期 48页 [查看摘要][在线阅读][下载 86K]
    [下载次数:18 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Micro-RNAs Regulate Metabolic Syndrome-induced Senescence in Adipose Tissue-derived Mesenchymal Stem Cells of through P16/MAPK Pathway

    Yu Meng;Alfonso Eirin;Lilach O.Lerman;

    Background Mesenchymal stem cells(MSC)constitute an important repair system,but may be impaired by exposure to cardiovascular risk factors.Consequently,adipose tissue-derived MSCs from pigs with the metabolic syndrome(Met S)show decreased vitality.A growing number of micro RNAs(mi RNAs)are recognized as key modulators of senescence,but their role in regulating senescence in MSC in Mets is unclear.We tested the hypothesis that Met S upregulates in MSC expression of mi RNAs that can serve as post-transcriptional regulators of senescence-associated(SA)genes.Methods MSCs were collected from swine abdominal adipose tissue after 16 weeks of Lean or Obese diet(n=6 each).Next-generation mi RNA sequencing(mi RNA-seq)was performed to identify mi RNAs up-or down-regulated in Met S-MSC compare to Lean-MSCs.Functional pathway analysis of SA genes targeted by mi RNAs was performed using gene ontology analysis.MSC senescence was evaluated by p16 and p21 immunoreactivity,H2AX protein expression,and SA-beta-Galactosidase activity.In addition,gene expression of p16,p21,MAPK3,and MAPK14 was studied after inhibition of SA-mi R-27b.Results Senescence biomarkers were significantly elevated in Met S MSC.We found the 7 upregulated mi RNAs,including mi R-27b,and 3 downregulated mi RNAs in Met S-MSCs,which regulate 35 SA genes,particularly MAPK signaling.Inhibition of mi R-27b in cultured MSC downregulated p16 and MARP3 genes.Conclusions Met S modulate MSC expression of SA-mi RNAs that may play the role in modulating their senescence,and the p16 pathway in Met S-MSCs senescence is the primary pathway.

    2017年S1期 48页 [查看摘要][在线阅读][下载 86K]
    [下载次数:18 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 西那卡塞联合活性维生素D治疗终末期肾脏病继发性甲状旁腺功能亢进疗效及安全性的Meta分析

    闫冰;黄盛玲;孟宇;尹良红;

    <正>慢性肾脏病(chronic kidney disease,CKD)因其高发病率、高住院率、高死亡率以及高治疗费用成为了威胁人类健康的重大疾病之一。而钙磷代谢紊乱所导致的继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)也是ESRD患者发生心脑血管事件的独立危险因素之一。西那卡塞及活性维生素D治疗终末期肾脏病继发性甲状旁腺功能亢进的作用机制各不相同,而两者联用是否取得更大疗效还尚未明确,本研究使用Meta分析及系统评价综合分析两者联用治疗的安全性及有效性。

    2017年S1期 61页 [查看摘要][在线阅读][下载 89K]
    [下载次数:158 ] |[网刊下载次数:0 ] |[引用频次:2 ] |[阅读次数:0 ]
  • 西那卡塞联合活性维生素D治疗终末期肾脏病继发性甲状旁腺功能亢进疗效及安全性的Meta分析

    闫冰;黄盛玲;孟宇;尹良红;

    <正>慢性肾脏病(chronic kidney disease,CKD)因其高发病率、高住院率、高死亡率以及高治疗费用成为了威胁人类健康的重大疾病之一。而钙磷代谢紊乱所导致的继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)也是ESRD患者发生心脑血管事件的独立危险因素之一。西那卡塞及活性维生素D治疗终末期肾脏病继发性甲状旁腺功能亢进的作用机制各不相同,而两者联用是否取得更大疗效还尚未明确,本研究使用Meta分析及系统评价综合分析两者联用治疗的安全性及有效性。

    2017年S1期 61页 [查看摘要][在线阅读][下载 89K]
    [下载次数:158 ] |[网刊下载次数:0 ] |[引用频次:2 ] |[阅读次数:0 ]

护理研究

  • 降低维持性血液透析患者不正确服用肠溶阿司匹林的护理专案

    李佛兰;钟影雪;王宝祥;黄洁薇;

    目的通过护理专案降低维持性血液透析患者不正确服用肠溶阿司匹林的发生率。方法通过人员、物品、方法、环境四方面对维持性血液透析患者不正确服用肠溶阿司匹林进行根本原因分析,结合临床护理工作,将专案目标设定为:2014年12月维持性血液透析患者不正确服用肠溶阿司匹林的发生率低于3.26%。确定解决方法及执行过程,如:组织理论讲座,选择适当的评估方法,规范指导患者服药流程,设立患者服药管理档案,规定评价效果的方法和时间。结果维持性血液透析患者不正确服用肠溶阿司匹林的发生率14.29%,降低到活动后的2.04%,对维持性血液透析患者肠溶阿司匹林服药评估达100%。结论通过护理专案活动,发挥团队合作精神,降低维持性血液透析患者不正确服用肠溶阿司匹林的发生率,提高维持性血液透析患者的专科护理质量。

    2017年S1期 28-29页 [查看摘要][在线阅读][下载 139K]
    [下载次数:60 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 降低维持性血液透析患者不正确服用肠溶阿司匹林的护理专案

    李佛兰;钟影雪;王宝祥;黄洁薇;

    目的通过护理专案降低维持性血液透析患者不正确服用肠溶阿司匹林的发生率。方法通过人员、物品、方法、环境四方面对维持性血液透析患者不正确服用肠溶阿司匹林进行根本原因分析,结合临床护理工作,将专案目标设定为:2014年12月维持性血液透析患者不正确服用肠溶阿司匹林的发生率低于3.26%。确定解决方法及执行过程,如:组织理论讲座,选择适当的评估方法,规范指导患者服药流程,设立患者服药管理档案,规定评价效果的方法和时间。结果维持性血液透析患者不正确服用肠溶阿司匹林的发生率14.29%,降低到活动后的2.04%,对维持性血液透析患者肠溶阿司匹林服药评估达100%。结论通过护理专案活动,发挥团队合作精神,降低维持性血液透析患者不正确服用肠溶阿司匹林的发生率,提高维持性血液透析患者的专科护理质量。

    2017年S1期 28-29页 [查看摘要][在线阅读][下载 139K]
    [下载次数:60 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]

综述

  • 尿激酶治疗自体动静脉内瘘血栓的应用进展

    刘欢;

    <正>近年来血液透析成为肾脏替代治疗中的主要治疗方式,而自体动静脉内瘘又是血液透析患者最主要的血管通路之一,被喻为血液透析患者的"生命线",具有并发症少,使用寿命长等优点[1]。动静脉内瘘血栓形成是其最常见的并发症,有文献表明,动静脉内瘘血栓发生率可高达14%~36%,是影响血液透析患者疗安全的独立危险因素[2]。其治疗手段包括手法按摩;药物溶栓;Fogarty导管取栓;手术切开取栓;内瘘重建[3],后三种方法虽然成功率较高,但存在操作复杂,创伤较大或费用昂贵等缺点[4]。近年来,国内外最常使用的是尿激酶溶栓,此

    2017年S1期 30-32页 [查看摘要][在线阅读][下载 200K]
    [下载次数:235 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 尿激酶治疗自体动静脉内瘘血栓的应用进展

    刘欢;

    <正>近年来血液透析成为肾脏替代治疗中的主要治疗方式,而自体动静脉内瘘又是血液透析患者最主要的血管通路之一,被喻为血液透析患者的"生命线",具有并发症少,使用寿命长等优点[1]。动静脉内瘘血栓形成是其最常见的并发症,有文献表明,动静脉内瘘血栓发生率可高达14%~36%,是影响血液透析患者疗安全的独立危险因素[2]。其治疗手段包括手法按摩;药物溶栓;Fogarty导管取栓;手术切开取栓;内瘘重建[3],后三种方法虽然成功率较高,但存在操作复杂,创伤较大或费用昂贵等缺点[4]。近年来,国内外最常使用的是尿激酶溶栓,此

    2017年S1期 30-32页 [查看摘要][在线阅读][下载 200K]
    [下载次数:235 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Application Status and Prospect of Bio-artificial Liver

    Xiaoyi Chen;Mingming Ma;Sibo Huang;Shuang Cui;Huanhuan Liu;Jun Ke;Shengling Huang;Xiangnan Dong;Huixia Yu;Yongpin Lu;Chen Yun;Yu Mong;Fanna Liu;B.Hocher;Hongwei Hu;Jie Shu;Lianghong Yin;

    Liver failure which can be caused by viral hepatitis,alcohol,drugs,metabolic diseases,autoimmune processes or other fac tors is the end stage of chronic liver disease.Although liver transplantation is currently considered to be the primary treatment measures of chronic liver disease.Due to donor shortages,surgical complications and immune rejection,cell therapy has been extensively studied.?Hepa tocyte transplantation and artificial liver have evolved into a simpler alternative to liver failure treatment.Artificial liver can be used as Liver replacement therapy in patients who were waiting for the liver transplantation with chronic liver disease.The ideal biological artificial liver must have the liver material metabolism,detoxification,synthesis and secretion and other functions.Nowadays bio-artificial liver has carried out a large number of clinical trials and get some progress.?This article is now discuss the status of bio-artificial liver and its re placement therapy prospects.

    2017年S1期 33-36页 [查看摘要][在线阅读][下载 245K]
    [下载次数:9 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Application Status and Prospect of Bio-artificial Liver

    Xiaoyi Chen;Mingming Ma;Sibo Huang;Shuang Cui;Huanhuan Liu;Jun Ke;Shengling Huang;Xiangnan Dong;Huixia Yu;Yongpin Lu;Chen Yun;Yu Mong;Fanna Liu;B.Hocher;Hongwei Hu;Jie Shu;Lianghong Yin;

    Liver failure which can be caused by viral hepatitis,alcohol,drugs,metabolic diseases,autoimmune processes or other fac tors is the end stage of chronic liver disease.Although liver transplantation is currently considered to be the primary treatment measures of chronic liver disease.Due to donor shortages,surgical complications and immune rejection,cell therapy has been extensively studied.?Hepa tocyte transplantation and artificial liver have evolved into a simpler alternative to liver failure treatment.Artificial liver can be used as Liver replacement therapy in patients who were waiting for the liver transplantation with chronic liver disease.The ideal biological artificial liver must have the liver material metabolism,detoxification,synthesis and secretion and other functions.Nowadays bio-artificial liver has carried out a large number of clinical trials and get some progress.?This article is now discuss the status of bio-artificial liver and its re placement therapy prospects.

    2017年S1期 33-36页 [查看摘要][在线阅读][下载 245K]
    [下载次数:9 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Advances in Diagnosis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

    Shufei Zeng;Yangyang Zang;Dezhen Chen;Baozhang Guan;Fanna Liu;Mingming Ma;Yu Mong;Huiyuan Zheng;Aiyun Cha;Xiangnan Dong;Huanhuan Liu;Taksui Wong;Shuang Cui;Tong Liu;Yongpin Lu;Chen Yun;Hongwei Hu;B.Hocher;W.Pommer;Zuhui Chen;Lianghong Yin;

    <正>1 Introduction Neuropsychiatric systemic lupus erythematosus(NPSLE)is a serious complication of systemic lupus erythematosus(SLE),with an incidence of about 30%to 40%[1].No matter early or late SLE patients are prone to concurrent,so early diagnosis and treatment of NPSLE is extremely important.

    2017年S1期 37-39页 [查看摘要][在线阅读][下载 173K]
    [下载次数:11 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Advances in Diagnosis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

    Shufei Zeng;Yangyang Zang;Dezhen Chen;Baozhang Guan;Fanna Liu;Mingming Ma;Yu Mong;Huiyuan Zheng;Aiyun Cha;Xiangnan Dong;Huanhuan Liu;Taksui Wong;Shuang Cui;Tong Liu;Yongpin Lu;Chen Yun;Hongwei Hu;B.Hocher;W.Pommer;Zuhui Chen;Lianghong Yin;

    <正>1 Introduction Neuropsychiatric systemic lupus erythematosus(NPSLE)is a serious complication of systemic lupus erythematosus(SLE),with an incidence of about 30%to 40%[1].No matter early or late SLE patients are prone to concurrent,so early diagnosis and treatment of NPSLE is extremely important.

    2017年S1期 37-39页 [查看摘要][在线阅读][下载 173K]
    [下载次数:11 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Innovation Requirements and Progress of Dialysis Water Treatment System

    Jun Ke;Lifong Yan;Taksui Wong;Bo Hu;Shuang Cui;Sibo Huang;Aiyun Cha;Jie Huang;Hongwei Hu;Dawen Yun;Shaofeng Huang;Jie Shu;Mingming Ma;Lianghong Yin;Xiangnan Dong;Chen Yun;Zuhui Chen;Fanna Liu;

    <正>With the development of medicine,people are becoming more and more aware of the quality of medical water supply,such as dial ysis water,dental water,preparation water,operating room water,supply room water.Therefore,People are constantly improving the water treatment system and its standardized,and the demand for dialysis water is also becoming more and more strict.Hemodialysis is an effective means of maintaining the life of renal failure patients,120~180L water will be used for a conventional dialysis treatment,and high flux dialysis will consume more.So

    2017年S1期 40-41页 [查看摘要][在线阅读][下载 133K]
    [下载次数:17 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • Innovation Requirements and Progress of Dialysis Water Treatment System

    Jun Ke;Lifong Yan;Taksui Wong;Bo Hu;Shuang Cui;Sibo Huang;Aiyun Cha;Jie Huang;Hongwei Hu;Dawen Yun;Shaofeng Huang;Jie Shu;Mingming Ma;Lianghong Yin;Xiangnan Dong;Chen Yun;Zuhui Chen;Fanna Liu;

    <正>With the development of medicine,people are becoming more and more aware of the quality of medical water supply,such as dial ysis water,dental water,preparation water,operating room water,supply room water.Therefore,People are constantly improving the water treatment system and its standardized,and the demand for dialysis water is also becoming more and more strict.Hemodialysis is an effective means of maintaining the life of renal failure patients,120~180L water will be used for a conventional dialysis treatment,and high flux dialysis will consume more.So

    2017年S1期 40-41页 [查看摘要][在线阅读][下载 133K]
    [下载次数:17 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • Peritoneal Dialysis: Prospects and Challenges

    Lifeng Yang;Jun Ke;Jie Huang;Hongwei Hu;Shaofeng Huang;Jie Shu;Bo Hu;Aiyun Cha;Xiangnan Dong;Guanmin Wu;Fanna Liu;Yu Chen;Huanhuan Liu;Mingming Ma;Taksui Wong;Lianghong Yin;Chen Yun;Shufei Zeng;Baozhang Guan;Zuhui Chen;

    <正>There are 3 kinds of Renal Replacement Therapy:hemodialysis,peritoneal dialysis and kidney transplantation.Although a kidney transplant would be the best solution,organ donations are limited and the transplanted organs can be rejected by the body.Hemodialysis is a widely recognized and near-universally available treatment method,however,the patient must make at least 3 weekly visits to a hospital to undergo treatment,with each session lasting on average around 4 hours.Consequently this can have an impact on the patients'life,including work and travel.Since the clinical populariza-

    2017年S1期 42-44页 [查看摘要][在线阅读][下载 167K]
    [下载次数:10 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Peritoneal Dialysis: Prospects and Challenges

    Lifeng Yang;Jun Ke;Jie Huang;Hongwei Hu;Shaofeng Huang;Jie Shu;Bo Hu;Aiyun Cha;Xiangnan Dong;Guanmin Wu;Fanna Liu;Yu Chen;Huanhuan Liu;Mingming Ma;Taksui Wong;Lianghong Yin;Chen Yun;Shufei Zeng;Baozhang Guan;Zuhui Chen;

    <正>There are 3 kinds of Renal Replacement Therapy:hemodialysis,peritoneal dialysis and kidney transplantation.Although a kidney transplant would be the best solution,organ donations are limited and the transplanted organs can be rejected by the body.Hemodialysis is a widely recognized and near-universally available treatment method,however,the patient must make at least 3 weekly visits to a hospital to undergo treatment,with each session lasting on average around 4 hours.Consequently this can have an impact on the patients'life,including work and travel.Since the clinical populariza-

    2017年S1期 42-44页 [查看摘要][在线阅读][下载 167K]
    [下载次数:10 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • The Research Progression of Calcitonin for the Therapy of Renal Osteodystrophy

    Yingyan LI;Sibo HUANG;Shengling HUANG;Shuang CUI;Xiangnan DONG;Yueling ZHU;Baozhang GUAN;Taksui WONG;Bing YAN;Bo HU;Xin CHEN;Shanshan LI;Fanna LIU;Huiyuan ZHENG;Tong LIU;Hongwei HU;Shaofeng HUANG;Shufei ZENG;Chen YUN;Wolfgang Pommer;Zuhui CHEN;Lianghong Y

    Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients.

    2017年S1期 45-48页 [查看摘要][在线阅读][下载 231K]
    [下载次数:10 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • The Research Progression of Calcitonin for the Therapy of Renal Osteodystrophy

    Yingyan LI;Sibo HUANG;Shengling HUANG;Shuang CUI;Xiangnan DONG;Yueling ZHU;Baozhang GUAN;Taksui WONG;Bing YAN;Bo HU;Xin CHEN;Shanshan LI;Fanna LIU;Huiyuan ZHENG;Tong LIU;Hongwei HU;Shaofeng HUANG;Shufei ZENG;Chen YUN;Wolfgang Pommer;Zuhui CHEN;Lianghong Y

    Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients.

    2017年S1期 45-48页 [查看摘要][在线阅读][下载 231K]
    [下载次数:10 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • The Pathogenesis of the Mechanism of FGF23 in Chronic Kidney Disease Patients with Vascular Calcification

    Shanshan LI;Wenyu GNOG;Sibo HUANG;Lianghong YIN;Bo HU;Xiangnan DONG;Taksui WONG;Fanna LIU;Yingyan LI;Yueling ZHU;Xin CHEN;Baozhang GUAN;Shengling HUANG;Shuang CUI;Bing YAN;Hongwei HU;Shaofeng HUANG;Yongpin LU;Shufei ZENG;Chen YUN;Berthold Hocher;Wolfgang

    Fibroblast growth factor 23(FGF23)is a protein synthesized by bone cell and the osteoblast with endocrine function.The main role of FGF23 is to regulate serum phosphorus and 1,25(OH)2 D3 levels,it also plays an important role in calcium and phosphorus metabolism.The role of FGF23 in renal disease is to inhibit of phosphorus reabsorption,promote urinary phosphorus excretion and maintain a stable blood phosphorus level.Patients with chronic kidney disease(CKD)have more risk to suffer cardiovascular disease(CVD)which is related to the abnormal metabolism of calcium and phosphorus.FGF23,as newly discovered cardiovascular risk marker,several studies have shown that FGF23 level associates with multiple cardiovascular risk factors in CKD patients,especially in CKD patients with vascular calcification.To explore its pathogenesis of vascular calcification in CKD patients is particularly important,and that may help to take appropriate measures to improve the prognosis of CKD patients.

    2017年S1期 49-51页 [查看摘要][在线阅读][下载 176K]
    [下载次数:14 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • The Pathogenesis of the Mechanism of FGF23 in Chronic Kidney Disease Patients with Vascular Calcification

    Shanshan LI;Wenyu GNOG;Sibo HUANG;Lianghong YIN;Bo HU;Xiangnan DONG;Taksui WONG;Fanna LIU;Yingyan LI;Yueling ZHU;Xin CHEN;Baozhang GUAN;Shengling HUANG;Shuang CUI;Bing YAN;Hongwei HU;Shaofeng HUANG;Yongpin LU;Shufei ZENG;Chen YUN;Berthold Hocher;Wolfgang

    Fibroblast growth factor 23(FGF23)is a protein synthesized by bone cell and the osteoblast with endocrine function.The main role of FGF23 is to regulate serum phosphorus and 1,25(OH)2 D3 levels,it also plays an important role in calcium and phosphorus metabolism.The role of FGF23 in renal disease is to inhibit of phosphorus reabsorption,promote urinary phosphorus excretion and maintain a stable blood phosphorus level.Patients with chronic kidney disease(CKD)have more risk to suffer cardiovascular disease(CVD)which is related to the abnormal metabolism of calcium and phosphorus.FGF23,as newly discovered cardiovascular risk marker,several studies have shown that FGF23 level associates with multiple cardiovascular risk factors in CKD patients,especially in CKD patients with vascular calcification.To explore its pathogenesis of vascular calcification in CKD patients is particularly important,and that may help to take appropriate measures to improve the prognosis of CKD patients.

    2017年S1期 49-51页 [查看摘要][在线阅读][下载 176K]
    [下载次数:14 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Progress in the Clinical Application of Cinacalcet in the Treatment of Secondary Hyperthyroidism

    Yueling ZHU;Shengling HUANG;Shuang Cui;Lianghong YIN;Taksui Wong;Xiangnan DONG;Bing YAN;Baozhang GUAN;Bo HU;Fanna LIU;Yingyan LI;Shanshan LI;Xin CHEN;Berthold Hocher;Wolfgang Pommer;

    Secondary hyperthyroidism(SHPT)is a common complication of maintenance hemodialysis(MHD).In China the prevalence of chronic kidney disease(CKD)is 10.8%and there are about 0.2 million patients treated with maintenance hemodialysis.These number are still increasing.Cinacalcet is a new calcium sensing receptor agonist to treat SHPT and the first calcimimetics be approved by Food and Drug Administration(FDA)to treat human.It can activate the calcium sensing receptor in parathyroid to improving control of parathyroid hormone(PTH),serum calcium,phosphorus,and calcium phosphorus product.Then decrease vascular calcification and parathyroid gland volume and reduce the occurrence of fracture and calcific uremic arteriolopathy(CUA).A better understanding of the clinical evaluation for Cinacalcet will hopefully help us to reduce the incidence of SHPT.

    2017年S1期 52-54页 [查看摘要][在线阅读][下载 188K]
    [下载次数:14 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Progress in the Clinical Application of Cinacalcet in the Treatment of Secondary Hyperthyroidism

    Yueling ZHU;Shengling HUANG;Shuang Cui;Lianghong YIN;Taksui Wong;Xiangnan DONG;Bing YAN;Baozhang GUAN;Bo HU;Fanna LIU;Yingyan LI;Shanshan LI;Xin CHEN;Berthold Hocher;Wolfgang Pommer;

    Secondary hyperthyroidism(SHPT)is a common complication of maintenance hemodialysis(MHD).In China the prevalence of chronic kidney disease(CKD)is 10.8%and there are about 0.2 million patients treated with maintenance hemodialysis.These number are still increasing.Cinacalcet is a new calcium sensing receptor agonist to treat SHPT and the first calcimimetics be approved by Food and Drug Administration(FDA)to treat human.It can activate the calcium sensing receptor in parathyroid to improving control of parathyroid hormone(PTH),serum calcium,phosphorus,and calcium phosphorus product.Then decrease vascular calcification and parathyroid gland volume and reduce the occurrence of fracture and calcific uremic arteriolopathy(CUA).A better understanding of the clinical evaluation for Cinacalcet will hopefully help us to reduce the incidence of SHPT.

    2017年S1期 52-54页 [查看摘要][在线阅读][下载 188K]
    [下载次数:14 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 慢性肾脏病与新发糖尿病前期的研究进展

    褚畅;黄德绪;尹良红;

    <正>糖尿病前期(Pre-DM)被定义为空腹血糖(FPG)处于100~125 mg/d L,餐后2小时血糖(2h PG)处于140~199mg/d L的糖代谢异常状态。早在上世纪90年代,Fliser D等~([1])首先发现慢性肾脏病(CKD)早期,甚至在肾小球滤过率处于正常范围时即可发生糖代谢紊乱,胰岛素抵抗(IR)随肾小球

    2017年S1期 55-57页 [查看摘要][在线阅读][下载 205K]
    [下载次数:133 ] |[网刊下载次数:0 ] |[引用频次:2 ] |[阅读次数:0 ]
  • 慢性肾脏病与新发糖尿病前期的研究进展

    褚畅;黄德绪;尹良红;

    <正>糖尿病前期(Pre-DM)被定义为空腹血糖(FPG)处于100~125 mg/d L,餐后2小时血糖(2h PG)处于140~199mg/d L的糖代谢异常状态。早在上世纪90年代,Fliser D等~([1])首先发现慢性肾脏病(CKD)早期,甚至在肾小球滤过率处于正常范围时即可发生糖代谢紊乱,胰岛素抵抗(IR)随肾小球

    2017年S1期 55-57页 [查看摘要][在线阅读][下载 205K]
    [下载次数:133 ] |[网刊下载次数:0 ] |[引用频次:2 ] |[阅读次数:0 ]
  • 对比超声技术检测肾脏血流灌注—评估肾脏损伤新进展

    崔爽;刘璠娜;孟宇;陈湛华;尹良红;

    对比超声技术(Contrast enhanced ultrasound,CEUS)是一种新型的血管造影成像技术,具有无创,无肾毒性,可床旁监测肾脏微循环血流灌注等优势。虽然CEUS技术可能是一种好的评估肾脏功能的手段,但仍需要系统评价其监测肾脏微循环灌注的应用价值。

    2017年S1期 58-59页 [查看摘要][在线阅读][下载 163K]
    [下载次数:69 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • 对比超声技术检测肾脏血流灌注—评估肾脏损伤新进展

    崔爽;刘璠娜;孟宇;陈湛华;尹良红;

    对比超声技术(Contrast enhanced ultrasound,CEUS)是一种新型的血管造影成像技术,具有无创,无肾毒性,可床旁监测肾脏微循环血流灌注等优势。虽然CEUS技术可能是一种好的评估肾脏功能的手段,但仍需要系统评价其监测肾脏微循环灌注的应用价值。

    2017年S1期 58-59页 [查看摘要][在线阅读][下载 163K]
    [下载次数:69 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • 小剂量甲状腺素治疗慢性肾脏病合并低T3综合征的研究进展

    李彩芳;尹良红;

    低T3综合征在慢性肾脏病(chronic kidney disease,CKD)中普遍存在,且可能与CKD患者的预后有一定的相关性。临床上对此类患者是否进行甲状腺激素治疗、患者从此治疗中获益如何,笔者将在此做一般的综述。

    2017年S1期 59页 [查看摘要][在线阅读][下载 96K]
    [下载次数:105 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]
  • 小剂量甲状腺素治疗慢性肾脏病合并低T3综合征的研究进展

    李彩芳;尹良红;

    低T3综合征在慢性肾脏病(chronic kidney disease,CKD)中普遍存在,且可能与CKD患者的预后有一定的相关性。临床上对此类患者是否进行甲状腺激素治疗、患者从此治疗中获益如何,笔者将在此做一般的综述。

    2017年S1期 59页 [查看摘要][在线阅读][下载 96K]
    [下载次数:105 ] |[网刊下载次数:0 ] |[引用频次:1 ] |[阅读次数:0 ]

病例报告

  • Treatment of Sepsis by Hemofiltration Combined with Plasma Exchange in One Case

    Weilong Li;Sibo Huang;Shuang Cui;Zongchao Yu;Shufei Zeng;Bo Hu;Aiyun Cha;Jian Li;Huixia Yu;Mingming Ma;Xiangnan Dong;Xiaoyi Chen;W.Pommer;Chen Yun;Lianghong Yin;

    <正>Female patients,44 years old,due to"regular peritoneal dialysis5 years,stomach ache 1 week"admission.Previous had 2 times for"Peritoneal dialysis related peritonitis"in hospital,after anti-infection treatment patients symptoms improved and discharged.1 week ago in patients admitted to hospital because of abdominal pain again.Physical:abdominal tenderness,bowel sounds hyperthyroidism.Laboratory inspection index:CRP:172.22 mg/l,WBC:23.26×10~9/L,NEU%:89.23%,D dimer:3 800 ng/ml,PCT:14.86 ng/ml,Ascites

    2017年S1期 60-61页 [查看摘要][在线阅读][下载 546K]
    [下载次数:13 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • Treatment of Sepsis by Hemofiltration Combined with Plasma Exchange in One Case

    Weilong Li;Sibo Huang;Shuang Cui;Zongchao Yu;Shufei Zeng;Bo Hu;Aiyun Cha;Jian Li;Huixia Yu;Mingming Ma;Xiangnan Dong;Xiaoyi Chen;W.Pommer;Chen Yun;Lianghong Yin;

    <正>Female patients,44 years old,due to"regular peritoneal dialysis5 years,stomach ache 1 week"admission.Previous had 2 times for"Peritoneal dialysis related peritonitis"in hospital,after anti-infection treatment patients symptoms improved and discharged.1 week ago in patients admitted to hospital because of abdominal pain again.Physical:abdominal tenderness,bowel sounds hyperthyroidism.Laboratory inspection index:CRP:172.22 mg/l,WBC:23.26×10~9/L,NEU%:89.23%,D dimer:3 800 ng/ml,PCT:14.86 ng/ml,Ascites

    2017年S1期 60-61页 [查看摘要][在线阅读][下载 546K]
    [下载次数:13 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 一例疑似C3肾小球病的病理诊断的探讨

    董向楠;尹良红;孟宇;刘璠娜;

    <正>病历概述:患者辛某某,男,11岁,因"确诊肾小球肾炎、间断尿常规异常1年余"入院进一步诊治,患者1年前因眼睑及双下肢浮肿2天入院治疗,入院前有咳嗽、咽痛病史,入院查心肺腹检查阴性,生命体征无异常,生化示:血浆白蛋白37.8 g/L,抗"O"(ASO)361.1 IU/ml,补体C3 38 mg/L,24小时尿蛋白0.26 g/d,诊断为急性链球菌感染后肾小球肾炎,

    2017年S1期 62页 [查看摘要][在线阅读][下载 946K]
    [下载次数:58 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 一例疑似C3肾小球病的病理诊断的探讨

    董向楠;尹良红;孟宇;刘璠娜;

    <正>病历概述:患者辛某某,男,11岁,因"确诊肾小球肾炎、间断尿常规异常1年余"入院进一步诊治,患者1年前因眼睑及双下肢浮肿2天入院治疗,入院前有咳嗽、咽痛病史,入院查心肺腹检查阴性,生命体征无异常,生化示:血浆白蛋白37.8 g/L,抗"O"(ASO)361.1 IU/ml,补体C3 38 mg/L,24小时尿蛋白0.26 g/d,诊断为急性链球菌感染后肾小球肾炎,

    2017年S1期 62页 [查看摘要][在线阅读][下载 946K]
    [下载次数:58 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]

  • 暨南大学附属第一医院肾内科简介

    <正>暨南大学附属第一医院肾脏内科创建于1978年,是广东省临床重点专科、广东省标准化血液净化培训基地和药物临床试验基地。广东省生物医学工程学会血液净化专业委员会主委单位及广东省女医师协会肾脏病和血液净化专业委员会主委单位。现有住院病80张,年出院人数三千余例次,年开展经皮肤肾穿刺活检近一百例,自己阅片发报告。年门诊人次八千余次,年血液净化三万多例次。本专科下设

    2017年S1期 63页 [查看摘要][在线阅读][下载 186K]
    [下载次数:13 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 暨南大学附属第一医院肾内科简介

    <正>暨南大学附属第一医院肾脏内科创建于1978年,是广东省临床重点专科、广东省标准化血液净化培训基地和药物临床试验基地。广东省生物医学工程学会血液净化专业委员会主委单位及广东省女医师协会肾脏病和血液净化专业委员会主委单位。现有住院病80张,年出院人数三千余例次,年开展经皮肤肾穿刺活检近一百例,自己阅片发报告。年门诊人次八千余次,年血液净化三万多例次。本专科下设

    2017年S1期 63页 [查看摘要][在线阅读][下载 186K]
    [下载次数:13 ] |[网刊下载次数:0 ] |[引用频次:0 ] |[阅读次数:0 ]
  • 下载本期数据